Medicinal products — List of marketing authorisations granted by the EEA EFTA States for the first half of 2017
Date: 2018-06-14
Institutions: Standing Committee of the EFTA States
Subjects: EFTA countries, European Economic Area, free movement of goods, market approval, medicinal product, withdrawal from the market








C_2018205EN.01000701.xml










14.6.2018   


EN


Official Journal of the European Union


C 205/7





Medicinal products — List of marketing authorisations granted by the EEA EFTA States for the first half of 2017
(2018/C 205/05)

Subcommittee I on the free movement of goods


To be noted by the EEA Joint Committee

With reference to EEA Joint Committee Decision No 74/1999 of 28 May 1999, the EEA Joint Committee is invited to note the following lists concerning marketing authorisations for medicinal products for the period 1 January-30 June 2017, at their meeting on 15 December 2017:






Annex I


List of new marketing authorisations




Annex II


List of renewed marketing authorisations




Annex III


List of extended marketing authorisations




Annex IV


List of withdrawn marketing authorisations




Annex V


List of suspended marketing authorisations






ANNEX I
List of new marketing authorisations
The following marketing authorisations have been granted in the EEA EFTA States during the period 1 January-30 June 2017:








EU Number


Product


Country


Date of authorisation




EU/1/11/699


Fampyra (Switch to non-conditional)


Liechtenstein


30.6.2017




EU/1/12/771


Zoledronsäure Teva


Liechtenstein


30.6.2017




EU/1/15/1049


Cystadrops


Liechtenstein


28.2.2017




EU/1/15/1049


Cystadrops


Norway


27.1.2017




EU/1/15/1049


CYSTADROPS


Iceland


30.1.2017




EU/1/15/1078


Natpar


Liechtenstein


30.4.2017




EU/1/15/1078


Natpar


Norway


10.5.2017




EU/1/15/1078


Natpar


Iceland


15.5.2017




EU/1/16/1086


TAGRISSO (Switch to non-conditional)


Liechtenstein


30.4.2017




EU/1/16/1110


Chenodeoxycholic acid Leadiant


Norway


20.4.2017




EU/1/16/1110


Chenodeoxycholic acid Leadiant


Liechtenstein


30.6.2017




EU/1/16/1110


Chenodeoxycholic acid Leadiant


Iceland


9.5.2017




EU/1/16/1133


Emtricitabine/Tenofovir disoproxil Mylan


Liechtenstein


28.2.2017




EU/1/16/1133


Emtricitabine/Tenofovir disoproxil Mylan


Norway


16.1.2017




EU/1/16/1133


Emtricitabine/Tenofovir disoproxil Mylan


Iceland


5.1.2017




EU/1/16/1139


OCALIVA


Liechtenstein


30.4.2017




EU/1/16/1140


Darunavir Mylan


Liechtenstein


28.2.2017




EU/1/16/1140


Darunavir Mylan


Norway


16.1.2017




EU/1/16/1140


Darunavir Mylan


Iceland


11.1.2017




EU/1/16/1150


Rekovelle


Norway


6.1.2017




EU/1/16/1150


REKOVELLE


Iceland


4.1.2017




EU/1/16/1152


Roteas


Liechtenstein


30.4.2017




EU/1/16/1152


Roteas


Norway


10.5.2017




EU/1/16/1152


Roteas


Iceland


10.5.2017




EU/1/16/1153


Tadalafil Generics


Liechtenstein


28.2.2017




EU/1/16/1153


Tadalafil Generics


Norway


24.1.2017




EU/1/16/1153


Tadalafil Generics


Iceland


13.1.2017




EU/1/16/1154


Vemlidy


Liechtenstein


28.2.2017




EU/1/16/1154


Vemlidy


Norway


1.2.2017




EU/1/16/1154


Vemlidy


Iceland


13.1.2017




EU/1/16/1156


ZINPLAVA


Liechtenstein


28.2.2017




EU/1/16/1156


ZINPLAVA


Norway


26.1.2017




EU/1/16/1156


Zinplava


Iceland


24.1.2017




EU/1/16/1157


Suliqua


Liechtenstein


28.2.2017




EU/1/16/1157


Suliqua


Norway


25.1.2017




EU/1/16/1157


Suliqua


Iceland


24.1.2017




EU/1/16/1158


AFSTYLA


Liechtenstein


28.2.2017




EU/1/16/1158


AFSTYLA


Norway


11.1.2017




EU/1/16/1158


Afstyla


Iceland


11.1.2017




EU/1/16/1159


Terrosa


Liechtenstein


28.2.2017




EU/1/16/1159


Terrosa


Norway


11.1.2017




EU/1/16/1159


Terrosa


Iceland


11.1.2017




EU/1/16/1160


Fiasp


Liechtenstein


28.2.2017




EU/1/16/1160


Fiasp


Norway


25.1.2017




EU/1/16/1160


Fiasp


Iceland


23.1.2017




EU/1/16/1161


Movymia


Liechtenstein


28.2.2017




EU/1/16/1161


Movymia


Norway


26.1.2017




EU/1/16/1161


Movymia


Iceland


24.1.2017




EU/1/16/1162


Lusduna


Liechtenstein


28.2.2017




EU/1/16/1162


Lusduna


Norway


19.1.2017




EU/1/16/1162


Lusduna


Iceland


12.1.2017




EU/1/16/1163


SOLYMBIC


Liechtenstein


30.4.2017




EU/1/16/1163


SOLYMBIC


Norway


6.4.2017




EU/1/16/1163


Solymbic


Iceland


6.4.2017




EU/1/16/1164


AMGEVITA


Liechtenstein


30.4.2017




EU/1/16/1164


AMGEVITA


Norway


6.4.2017




EU/1/16/1164


Amgevita


Iceland


6.4.2017




EU/1/16/1165


LIFMIOR


Liechtenstein


28.2.2017




EU/1/16/1165


LIFMIOR


Norway


21.2.2017




EU/1/16/1165


Lifmior


Iceland


21.2.2017




EU/1/16/1166


Pregabalin Zentiva k.s


Liechtenstein


30.4.2017




EU/1/16/1166


Pregabalin Zentiva k.s.


Norway


13.3.2017




EU/1/16/1166


Pregabalin Zentiva k.s.


Iceland


14.3.2017




EU/1/16/1167


Truxima


Liechtenstein


30.4.2017




EU/1/16/1167


Truxima


Norway


28.2.2017




EU/1/16/1167


Truxima


Iceland


15.3.2017




EU/1/16/1168


Vihuma


Liechtenstein


30.4.2017




EU/1/16/1168


Vihuma


Norway


17.3.2017




EU/1/16/1168


Vihuma


Iceland


10.3.2017




EU/1/16/1169


Alecensa


Liechtenstein


28.2.2017




EU/1/16/1169


Alecensa


Norway


7.3.2017




EU/1/16/1169


Alecensa


Iceland


15.3.2017




EU/1/16/1170


Olumiant


Liechtenstein


28.2.2017




EU/1/16/1170


Olumiant


Norway


22.2.2017




EU/1/16/1170


OLUMIANT


Iceland


21.2.2017




EU/1/16/1171


Ledaga


Liechtenstein


30.4.2017




EU/1/16/1171


Ledaga


Norway


15.3.2017




EU/1/16/1171


LEDAGA


Iceland


14.3.2017




EU/1/17/1172


Jylamvo


Liechtenstein


30.4.2017




EU/1/17/1172


Jylamvo


Norway


4.4.2017




EU/1/17/1172


Jylamvo


Iceland


26.4.2017




EU/1/17/1174


Rolufta


Liechtenstein


30.4.2017




EU/1/17/1174


Rolufta


Norway


7.4.2017




EU/1/17/1174


Rolufta


Iceland


24.3.2017




EU/1/17/1175


Daptomycin Hospira


Liechtenstein


30.4.2017




EU/1/17/1175


Daptomycin Hospira


Norway


18.4.2017




EU/1/17/1175


Daptomycin Hospira


Iceland


7.4.2017




EU/1/17/1176


Yargesa


Liechtenstein


30.4.2017




EU/1/17/1176


Yargesa


Norway


7.4.2017




EU/1/17/1176


Yargesa


Iceland


7.4.2017




EU/1/17/1177


Tadalafil Lilly


Liechtenstein


30.4.2017




EU/1/17/1177


Tadalafil Lilly


Norway


18.4.2017




EU/1/17/1177


Tadalafil Lilly


Iceland


6.4.2017




EU/1/17/1178


Xeljanz


Liechtenstein


30.4.2017




EU/1/17/1178


Xeljanz


Norway


6.4.2017




EU/1/17/1178


XELJANZ


Iceland


6.4.2017




EU/1/17/1180


Varuby


Liechtenstein


30.4.2017




EU/1/17/1180


Varuby


Norway


10.5.2017




EU/1/17/1180


Varuby


Iceland


10.5.2017




EU/1/17/1182


Emtricitabine/Tenofovir disoproxil Krka d.d.


Liechtenstein


30.6.2017




EU/1/17/1182


Emtricitabine/Tenofovir disoproxil Krka d.d.


Norway


22.5.2017




EU/1/17/1182


Emtricitabine/Tenofovir disoproxil KrKa d.d.


Iceland


12.5.2017




EU/1/17/1183


Pemetrexed Hospira UK Limited


Norway


9.5.2017




EU/1/17/1183


Pemetrexed Hospira UK Limited


Iceland


12.5.2017




EU/1/17/1183


Pemetrexed Hospira UK Ltd


Liechtenstein


30.6.2017




EU/1/17/1184


Riximyo


Liechtenstein


30.6.2017




EU/1/17/1184


Riximyo


Norway


26.6.2017




EU/1/17/1185


Rixathon


Liechtenstein


30.6.2017




EU/1/17/1185


Rixathon


Norway


23.6.2017




EU/1/17/1186


Axumin


Liechtenstein


30.6.2017




EU/1/17/1186


Axumin


Norway


31.5.2017




EU/1/17/1186


Axumin


Iceland


21.6.2017




EU/1/17/1187


Trumenba


Liechtenstein


30.6.2017




EU/1/17/1187


Trumenba


Norway


9.6.2017




EU/1/17/1187


Trumenba


Iceland


21.6.2017




EU/1/17/1188


Spinraza


Liechtenstein


30.6.2017




EU/1/17/1188


Spinraza


Norway


8.6.2017




EU/1/17/1188


Spinraza


Iceland


30.6.2017




EU/1/17/1189


Elmiron


Liechtenstein


30.6.2017




EU/1/17/1189


Elmiron


Norway


20.6.2017




EU/1/17/1189


Elmiron


Iceland


30.6.2017




EU/1/17/1190


Ivabradine Accord


Liechtenstein


30.6.2017




EU/1/17/1190


Ivabradine Accord


Norway


12.6.2017




EU/1/17/1190


Ivabradine Accord


Iceland


7.6.2017




EU/1/17/1191


Dinutuximab beta Apeiron


Liechtenstein


30.6.2017




EU/1/17/1191


Dinutuximab beta Apeiron


Norway


12.5.2017




EU/1/17/1191


Dinutuximab beta Apeiron


Iceland


23.5.2017




EU/1/17/1192


Brineura


Liechtenstein


30.6.2017




EU/1/17/1192


Brineura


Norway


6.6.2017




EU/1/17/1192


Brineura


Iceland


30.6.2017




EU/1/17/1193


Refixia


Liechtenstein


30.6.2017




EU/1/17/1193


Refixia


Norway


22.6.2017




EU/1/17/1193


Refixia


Iceland


30.6.2017




EU/1/17/1194


Febuxostat Mylan


Liechtenstein


30.6.2017




EU/1/17/1194


Febuxostat Mylan


Norway


26.6.2017




EU/1/17/1195


Erelzi


Liechtenstein


30.6.2017




EU/1/17/1196


Kevzara


Liechtenstein


30.6.2017




EU/1/17/1201


Skilarence


Liechtenstein


30.6.2017




EU/1/17/1202


Ucedane


Liechtenstein


30.6.2017




EU/2/16/200


Cepedex


Norway


4.1.2017




EU/2/16/201


Halagon


Norway


4.1.2017




EU/2/16/201


Halagon


Iceland


4.1.2017




EU/2/16/202


Coliprotec F4/F18


Liechtenstein


28.2.2017




EU/2/16/202


Coliprotec F4/F18


Norway


21.2.2017




EU/2/16/202


Coliprotec F4/F18


Iceland


9.3.2017




EU/2/16/203


VarroMed


Liechtenstein


28.2.2017




EU/2/16/203


VarroMed


Norway


21.2.2017




EU/2/16/203


VarroMed


Iceland


15.2.2017




EU/2/16/204


Stronghold Plus


Liechtenstein


28.2.2017




EU/2/16/204


Stronghold Plus


Norway


27.2.2017




EU/2/16/204


Stronghold Plus


Iceland


15.2.2017




EU/2/17/205


CYTOPOINT


Liechtenstein


30.4.2017




EU/2/17/205


CYTOPOINT


Norway


23.5.2017




EU/2/17/205


CYTOPOINT


Iceland


12.5.2017




EU/2/17/206


Credelio


Liechtenstein


30.6.2017




EU/2/17/206


Credelio


Norway


23.5.2017




EU/2/17/206


Credelio


Iceland


12.5.2017




EU/2/17/207


Zulvac BTV Ovis


Norway


18.5.2017




EU/2/17/207


Zulvac BTV Ovis


Iceland


12.5.2017




EU/2/17/208


Ingelvac PCV FLEX


Liechtenstein


30.6.2017




EU/2/17/208


Ingelvac PCV FLEX


Norway


8.6.2017




EU/2/17/208


Ingelvac PCV FLEX


Iceland


13.6.2017




EU/2/17/209


RESPIPORC FLUpan H1N1


Liechtenstein


30.6.2017




EU/2/17/209


RESPIPORC FLUpan H1N1


Norway


2.6.2017




EU/2/17/209


RESPIPORC FLUpan H1N1


Iceland


13.6.2017




EU/2/17/210


Zeleris


Norway


7.6.2017




EU/2/17/210


Zeleris


Iceland


19.5.2017







ANNEX II
List of renewed marketing authorisations
The following marketing authorisations have been renewed in the EEA EFTA States during the period 1 January-30 June 2017:








EU Number


Product


Country


Date of authorisation




EU/1/02/226


InductosOs


Liechtenstein


30.6.2017




EU/1/06/362


Byetta


Norway


24.1.2017




EU/1/06/364


Adrovance


Norway


28.3.2017




EU/1/06/365


Elaprase


Norway


23.1.2016




EU/1/06/366


Tandemact


Norway


27.1.2017




EU/1/07/388


Sebivo


Liechtenstein


28.2.2017




EU/1/07/388


Sebivo


Norway


16.1.2017




EU/1/07/388


Sebivo


Iceland


5.1.2017




EU/1/07/391


Revlimid


Liechtenstein


28.2.2017




EU/1/07/391


Revlimid


Norway


23.2.2017




EU/1/07/391


Revlimid


Iceland


21.2.2017




EU/1/07/396


Pergoveris


Liechtenstein


30.6.2017




EU/1/07/396


Pergoveris


Norway


23.5.2017




EU/1/07/396


Pergoveris


Iceland


23.5.2017




EU/1/07/397


Siklos


Liechtenstein


30.4.2017




EU/1/07/397


Siklos


Norway


5.5.2017




EU/1/07/397


Siklos


Iceland


11.5.2017




EU/1/07/403


Atriance


Liechtenstein


30.6.2017




EU/1/07/403


Atriance


Norway


26.6.2017




EU/1/07/404


Flebogamma DIF


Liechtenstein


30.4.2017




EU/1/07/404


Flebogamma DIF


Norway


10.5.2017




EU/1/07/404


Flebogamma DIF


Iceland


11.5.2017




EU/1/07/405


Rasilez


Liechtenstein


30.6.2017




EU/1/07/405


Rasilez


Norway


12.6.2017




EU/1/07/405


Rasilez


Iceland


6.6.2017




EU/1/11/699


Fampyra


Norway


20.6.2017




EU/1/11/699


Fampyra


Iceland


6.6.2017




EU/1/11/749


Caprelsa


Liechtenstein


28.2.2017




EU/1/11/749


Caprelsa


Norway


2.3.2017




EU/1/11/749


Caprelsa


Iceland


24.2.2017




EU/1/12/752


Vepacel


Liechtenstein


28.2.2017




EU/1/12/752


Vepacel


Norway


19.1.2017




EU/1/12/752


Vepacel


Iceland


12.1.2017




EU/1/12/757


Pioglitazon Teva


Liechtenstein


30.4.2017




EU/1/12/757


Pioglitazone Teva


Norway


21.3.2017




EU/1/12/757


Pioglitazone Teva


Iceland


10.3.2017




EU/1/12/758


Pioglitazon Teva Pharma


Liechtenstein


30.4.2017




EU/1/12/758


Pioglitazone Teva Pharma


Norway


17.3.2017




EU/1/12/758


Pioglitazone Teva Pharma


Iceland


10.3.2017




EU/1/12/759


Zoledronic acid Actavis


Norway


4.1.2017




EU/1/12/759


Zoledronic acid Actavis


Iceland


4.1.2017




EU/1/12/760


Bronchitol


Liechtenstein


28.2.2017




EU/1/12/760


Bronchitol


Norway


23.1.2017




EU/1/12/760


Bronchitol


Iceland


23.1.2017




EU/1/12/761


Capecitabin Teva


Liechtenstein


28.2.2017




EU/1/12/761


Capecitabine Teva


Norway


25.1.2017




EU/1/12/761


Capecitabine Teva


Iceland


23.1.2017




EU/1/12/762


Capecitabin Accord


Liechtenstein


28.2.2017




EU/1/12/762


Capecitabine Accord


Norway


25.1.2017




EU/1/12/762


Capecitabine Accord


Iceland


23.1.2017




EU/1/12/763


Ecansya


Iceland


4.1.2017




EU/1/12/764


Pixuvri


Liechtenstein


30.4.2017




EU/1/12/764


Pixuvri


Norway


29.3.2017




EU/1/12/764


Pixuvri


Iceland


6.4.2017




EU/1/12/766


SANCUSO


Liechtenstein


28.2.2017




EU/1/12/766


SANCUSO


Norway


23.1.2017




EU/1/12/766


Sancuso


Iceland


13.1.2017




EU/1/12/767


Nimenrix


Liechtenstein


30.4.2017




EU/1/12/767


Nimenrix


Norway


14.3.2017




EU/1/12/767


Nimenrix


Iceland


14.3.2017




EU/1/12/768


Riluzol Zentiva


Liechtenstein


28.2.2017




EU/1/12/768


Riluzole Zentiva


Norway


24.1.2017




EU/1/12/768


Riluzole Zentiva


Iceland


13.1.2017




EU/1/12/769


Docetaxel Accord


Norway


3.3.2017




EU/1/12/769


Docetaxel Accord


Iceland


10.3.2017




EU/1/12/770


Docetaxel Kabi


Liechtenstein


30.4.2017




EU/1/12/770


Docetaxel Kabi


Norway


3.3.2017




EU/1/12/770


Docetaxel Kabi


Iceland


10.3.2017




EU/1/12/771


Zoledronic acid Teva


Norway


20.6.2017




EU/1/12/771


Zoledronic Acid Teva


Iceland


6.6.2017




EU/1/12/772


Zoledronic acid Teva Pharma


Norway


20.6.2017




EU/1/12/772


Zoledronic acid Teva Pharma


Iceland


6.6.2017




EU/1/12/772


Zoledronsäure Teva Pharma


Liechtenstein


30.6.2017




EU/1/12/773


Jakavi


Liechtenstein


30.6.2017




EU/1/12/773


Jakavi


Norway


12.5.2017




EU/1/12/773


Jakavi


Iceland


11.5.2017




EU/1/12/775


NovoThirteen


Liechtenstein


30.6.2017




EU/1/12/775


NovoThirteen


Norway


15.6.2017




EU/1/12/775


NovoThirteen


Iceland


7.6.2017




EU/1/12/776


Fycompa


Liechtenstein


30.4.2017




EU/1/12/776


Fycompa


Norway


18.4.2017




EU/1/12/776


Fycompa


Iceland


24.4.2017




EU/1/12/777


Inlyta


Liechtenstein


30.6.2017




EU/1/12/777


Inlyta


Norway


14.6.2017




EU/1/12/777


Inlyta


Iceland


8.6.2017




EU/1/12/778


Eklira Genuair


Liechtenstein


30.4.2017




EU/1/12/778


Eklira Genuair


Norway


10.5.2017




EU/1/12/778


Eklira Genuair


Iceland


10.5.2017




EU/1/12/779


Zoledronic acid medac


Iceland


18.5.2017




EU/1/12/779


Zoledronsäure medac


Liechtenstein


30.6.2017




EU/1/12/779


Zoledronsyre medac


Norway


22.5.2017




EU/1/12/780


Jentadueto


Liechtenstein


30.4.2017




EU/1/12/780


Jentadueto


Norway


6.4.2017




EU/1/12/780


Jentadueto


Iceland


6.4.2017




EU/1/12/781


Bretaris Genuair


Liechtenstein


30.4.2017




EU/1/12/781


Bretaris Genuair


Norway


10.5.2017




EU/1/12/781


Bretaris Genuair


Iceland


10.5.2017




EU/1/12/782


Kalydeco


Liechtenstein


30.6.2017




EU/1/12/782


Kalydeco


Norway


19.5.2017




EU/1/12/782


Kalydeco


Iceland


11.5.2017




EU/1/12/783


Zyclara


Liechtenstein


30.4.2017




EU/1/12/783


Zyclara


Norway


6.4.2017




EU/1/12/783


Zyclara


Iceland


7.4.2017




EU/1/12/785


Zinforo


Liechtenstein


30.6.2017




EU/1/12/785


Zinforo


Norway


19.5.2017




EU/1/12/785


Zinforo


Iceland


11.5.2017




EU/1/12/786


Zoledronic acid Mylan


Norway


26.6.2017




EU/1/12/786


Zoledronic acid Mylan


Iceland


7.6.2017




EU/1/12/786


Zoledronsäure Mylan


Liechtenstein


30.6.2017




EU/1/12/787


Revestive


Liechtenstein


30.6.2017




EU/1/12/792


Dacogen


Liechtenstein


30.6.2017




EU/1/12/792


Dacogen


Norway


1.6.2017




EU/1/12/792


Dacogen


Iceland


6.6.2017




EU/1/12/802


Capecitabin medac


Liechtenstein


30.6.2017




EU/1/12/802


Capecitabine medac


Norway


26.6.2017




EU/1/13/818


Bosulif


Liechtenstein


30.4.2017




EU/1/13/818


Bosulif


Norway


5.4.2017




EU/1/13/818


Bosulif


Iceland


7.4.2017




EU/1/13/875


Deltyba


Liechtenstein


30.4.2017




EU/1/13/875


Deltyba


Norway


14.3.2017




EU/1/13/875


Deltyba


Iceland


14.3.2017




EU/1/13/890


Cometriq


Liechtenstein


28.2.2017




EU/1/13/890


Cometriq


Iceland


23.1.2017




EU/1/13/901


Sirturo


Liechtenstein


28.2.2017




EU/1/13/901


Sirturo


Norway


11.5.2017




EU/1/13/901


SIRTURO


Iceland


6.1.2017




EU/1/13/902


Translarna


Liechtenstein


28.2.2017




EU/1/13/902


Translarna


Liechtenstein


30.6.2017




EU/1/13/902


Translarna


Norway


1.2.2017




EU/1/14/987


Holoclar


Norway


4.1.2017




EU/1/14/987


Holoclar


Iceland


4.1.2017




EU/1/15/999


Zykadia


Liechtenstein


30.4.2017




EU/1/15/999


Zykadia


Norway


30.5.2017




EU/1/15/999


Zykadia


Iceland


21.4.2017




EU/1/16/1086


Tagrisso


Norway


2.1.2017




EU/1/16/1089


Pandemic influenza vaccine H5N1 MedImmune


Iceland


10.5.2017




EU/1/16/1089


Pandemic influenza vaccine H5N1 MedImmune


Liechtenstein


30.4.2017




EU/1/16/1089


Pandemic Influenza Vaccine H5N1 MedImmune


Norway


29.6.2017




EU/1/16/1101


Darzalex


Liechtenstein


30.4.2017




EU/1/16/1101


Darzalex


Norway


12.5.2017




EU/1/16/1101


Darzalex


Iceland


11.5.2017




EU/2/07/072


Suprelorin


Liechtenstein


30.6.2017




EU/2/07/072


Suprelorin


Norway


2.6.2017




EU/2/07/072


Suprelorin


Iceland


23.5.2017




EU/2/11/137


Activyl Tick Plus


Iceland


4.1.2017




EU/2/12/139


Zulvac 1+8 Bovis


Norway


3.1.2017




EU/2/12/140


Poulvac E. coli


Liechtenstein


30.6.2017




EU/2/12/140


Poulvac E. Coli


Iceland


23.5.2017




EU/2/12/140


Poulvac E.coli


Norway


23.5.2017




EU/2/12/141


Porcilis ColiClos


Liechtenstein


30.4.2017




EU/2/12/141


Porcilis ColiClos


Norway


28.4.2017




EU/2/12/141


Porcilis ColiClos


Iceland


10.4.2017




EU/2/12/142


Cardalis


Liechtenstein


30.6.2017




EU/2/12/142


Cardalis


Norway


28.6.2017




EU/2/12/143


Nobivac L4


Norway


20.3.2017




EU/2/12/143


Nobivac L4


Liechtenstein


30.4.2017




EU/2/12/143


Nobivac L4


Iceland


24.3.2017







ANNEX III
List of extended marketing authorisations
The following marketing authorisations have been extended in the EEA EFTA States during the period 1 January-30 June 2017:








EU Number


Product


Country


Date of authorisation




EU/1/03/256/020


Humira


Norway


6.4.2017




EU/1/03/256/020


Humira


Iceland


10.4.2017




EU/1/07/396/004-006


Pergoveris


Norway


8.5.2017




EU/1/07/396/004-006


Pergoveris


Iceland


23.5.2017




EU/1/09/514/021-023


Zebinix


Iceland


4.1.2017




EU/1/09/514/024


Zebinix


Norway


4.1.2017




EU/1/09/564/004


Ilaris


Norway


7.3.2017




EU/1/09/564/004


Ilaris


Iceland


14.3.2017




EU/1/10/641/002


Ruconest


Norway


26.1.2017




EU/1/10/641/002


Ruconest


Iceland


30.1.2017




EU/1/10/655/012-014


Brilique


Norway


18.5.2017




EU/1/10/655/012-014


Brilique


Iceland


6.6.2017




EU/1/11/667/005-011


Esbriet


Norway


9.5.2017




EU/1/11/667/005-011


Esbriet


Iceland


11.5.2017




EU/1/13/860/003


Nexium Control


Norway


23.6.2017




EU/1/13/892/003-006


Tivicay


Norway


2.3.2017




EU/1/13/892/003-006


Tivicay


Iceland


13.3.2017




EU/1/15/1016/006-007


Repatha


Norway


17.2.2017




EU/1/15/1016/006-007


Repatha


Iceland


24.2.2017




EU/1/15/1074/005


Benepali


Norway


31.5.2017




EU/1/15/1074/005


Benepali


Iceland


7.6.2017




EU/1/97/047/009


BeneFIX


Norway


22.3.2017




EU/1/97/047/009


BeneFIX


Iceland


7.4.2017




EU/2/04/042/015-018


Novem


Iceland


6.6.2017




EU/2/08/083/006-009


EQUIOXX


Norway


9.2.2017




EU/2/08/083/006-009


Equioxx


Iceland


15.2.2017







ANNEX IV
List of withdrawn marketing authorisations
The following marketing authorisations have been withdrawn in the EEA EFTA States during the period 1 January-30 June 2017:








EU Number


Product


Country


Date of withdrawal




EU/1/00/137


Avandia


Liechtenstein


28.2.2017




EU/1/03/258


Avandamet


Liechtenstein


28.2.2017




EU/1/06/373


Imprida


Liechtenstein


30.4.2017




EU/1/06/373


Imprida


Norway


19.4.2017




EU/1/06/373


Imprida


Iceland


21.4.2017




EU/1/07/385


Focetria


Liechtenstein


28.2.2017




EU/1/08/500


Fablyn


Liechtenstein


28.2.2017




EU/1/09/512


Removab


Liechtenstein


30.6.2017




EU/1/09/512


Removab


Norway


23.6.2017




EU/1/09/512


Removab


Iceland


12.6.2017




EU/1/09/532


Clopidogrel Acino


Liechtenstein


28.2.2017




EU/1/09/532


Clopidogrel Acino


Norway


9.2.2017




EU/1/09/532


Clopidogrel Acino


Iceland


3.2.2017




EU/1/09/561


Clopidogrel Teva Pharma


Liechtenstein


30.6.2017




EU/1/09/561


Clopidogrel Teva Pharma


Norway


28.6.2017




EU/1/10/657


Prepandemic Influenza


Liechtenstein


28.2.2017




EU/1/11/720


Incivo


Iceland


3.2.2017




EU/1/11/721


Paglitaz


Liechtenstein


28.2.2017




EU/1/14/942


Clopidogrel/Acetylsalicylsäure Teva


Liechtenstein


28.2.2017




EU/1/14/948


Budesonide/Formoterol Teva


Norway


19.1.2017




EU/1/14/948


Budesonide/Formoterol Teva


Iceland


5.1.2017




EU/1/14/949


Vylaer Spiromax


Liechtenstein


28.2.2017




EU/1/14/949


Vylaer Spiromax


Norway


19.1.2017




EU/1/14/949


Vylaer Spiromax


Iceland


13.1.2017




EU/1/14/950


Budesonide/Formoterol Teva Pharma B.V.


Norway


19.1.2017




EU/1/14/950


Budesonide/Formoterol Teva Pharma B.V.


Iceland


5.1.2017




EU/1/15/1022


Unituxin


Norway


19.4.2017




EU/1/15/1022


Unituxin


Iceland


6.4.2017




EU/1/15/995


DUTREBIS


Liechtenstein


30.4.2017




EU/1/15/995


DUTREBIS


Norway


9.5.2017




EU/1/15/995


DUTREBIS


Iceland


11.5.2017




EU/2/11/127


RECUVYRA


Iceland


3.2.2017







ANNEX V
List of suspended marketing authorisations
The following marketing authorisations have been suspended in the EEA EFTA States during the period 1 January-30 June 2017:








EU Number


Product


Country


Date of suspension